tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Value
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Smart Value
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

AnaptysBio price target raised to $42 from $36 at JPMorgan
The FlyAnaptysBio price target raised to $42 from $36 at JPMorgan
7d ago
ANAB
Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
PremiumRatings
Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
8d ago
ANAB
AnaptysBio price target raised to $52 from $36 at Guggenheim
PremiumThe Fly
AnaptysBio price target raised to $52 from $36 at Guggenheim
9d ago
ANAB
AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating
PremiumRatings
AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating
10d ago
ANAB
Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions
PremiumRatings
Cautious Hold Rating on AnaptysBio Amid Uncertain Clinical Trial Outcomes and Strategic Decisions
12d ago
ANAB
AnaptysBio Reports Strong Progress in Clinical Trials
PremiumCompany AnnouncementsAnaptysBio Reports Strong Progress in Clinical Trials
13d ago
ANAB
AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst
Premium
Ratings
AnaptysBio’s Promising Clinical Trials and Strong Financial Position Earn ‘Buy’ Rating from Analyst
13d ago
ANAB
AnaptysBio reports Q4 EPS (72c), consensus ($1.70)
Premium
The Fly
AnaptysBio reports Q4 EPS (72c), consensus ($1.70)
13d ago
ANAB
ANAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
ANAB Earnings Report this Week: Is It a Buy, Ahead of Earnings?
15d ago
ANAB
AnaptysBio’s Promising Prospects Highlighted by Recent Data: A Buy Recommendation by David Risinger
PremiumRatings
AnaptysBio’s Promising Prospects Highlighted by Recent Data: A Buy Recommendation by David Risinger
17d ago
ANAB
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline
PremiumRatings
Positive Outlook on AnaptysBio: Buy Rating Based on Undervaluation and Promising Pipeline
27d ago
ANAB
AnaptysBio price target raised to $51 from $40 at Wells Fargo
PremiumThe Fly
AnaptysBio price target raised to $51 from $40 at Wells Fargo
27d ago
ANAB
Positive Phase 2 Trial Results and Strong Safety Profile Boost Confidence in AnaptysBio’s Rosnilimab, Supporting Buy Rating and Increased Price Target
PremiumRatingsPositive Phase 2 Trial Results and Strong Safety Profile Boost Confidence in AnaptysBio’s Rosnilimab, Supporting Buy Rating and Increased Price Target
27d ago
ANAB
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
Premium
The Fly
AnaptysBio price target raised to $22 from $19 at H.C. Wainwright
28d ago
ANAB
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
Premium
The Fly
Truist says AnaptysBio handing of placebo ‘raise doubt’ about Phase 2 RA data
28d ago
ANAB
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results
PremiumCompany Announcements
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results
28d ago
8K
ANAB
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
PremiumThe Fly
AnaptysBio announces Phase 2b RENOIR trial met primary endpoint
28d ago
ANAB
AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships
PremiumRatings
AnaptysBio’s Strong Financial Prospects Driven by Jemperli’s Growth and Strategic Partnerships
1M ago
ANAB
Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges
PremiumRatings
Hold Rating for AnaptysBio: Strategic Licensing Decision Amid Limited GPP Market and Competitive Challenges
1M ago
ANAB
AnaptysBio initiated with an Outperform at Wolfe Research
PremiumThe FlyAnaptysBio initiated with an Outperform at Wolfe Research
1M ago
ANAB
AnaptysBio initiated with an Outperform at Wolfe Research
Premium
The Fly
AnaptysBio initiated with an Outperform at Wolfe Research
1M ago
ANAB
AnaptysBio Partners with Vanda for Imsidolimab Development
Premium
Company Announcements
AnaptysBio Partners with Vanda for Imsidolimab Development
1M ago
8K
ANAB

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >